Announcement of Signing of Exclusive Agreement on the Triglyceride Deposit Cardiomyovasculopathy Therapeutic Drug “CNT-01” between TOA EIYO and Osaka University
TOA EIYO Ltd. (Head Office: Chuo-ku, Tokyo; President: Atsuo Takahashi; hereinafter, referred to as “TOA EIYO”) and National University Corporation Osaka University (Location: Suita-shi, Osaka; President: Shojiro Nishio; hereinafter, referred to as “Osaka University”) hereby announce that the parties signed an agreement on February 17, 2020 concerning the worldwide exclusive rights for development, manufacturing, and marketing of Triglyceride Deposit Cardiomyovasculopathy (hereinafter, referred to as “TGCV”) therapeutic drug “CNT-01.”
Based on this agreement, TOA EIYO will make upfront and milestone payments for Osaka University. After launch, TOA EIYO will also pay royalties on product sales.
CNT-01 is a TGCV therapeutic drug developed in an academic setting by CNT Laboratory (http://www.cnt-osaka.com/) of the Graduate School of Medicine at Osaka University and the Department of Pharmacy/Department of Medical Innovation at Osaka University Hospital, with the support of the Practical Research Project for Rare/Intractable Diseases of AMED (Japan Agency for Medical Research and Development), and for which a Phase II clinical trial is currently in progress in Japan. Seeking a collaboratory partner with strength in the cardiovascular field to realize the development, manufacturing, and marketing of CNT-01, the Graduate School of Medicine at Osaka University has chosen TOA EIYO as its partner. TOA EIYO plans to promote the development of CNT-01 using the experience it has gained through new drug research and development in the cardiovascular field.
TGCV is a new disease discovered by Assistant Professor Ken-ichi Hirano, et al. at the Department of Cardiovascular Medicine at Osaka University’s Graduate School of Medicine in 2008, through heart transplantation patients in Japan. This is a serious disease with a poor prognosis, including severe heart failure, arrhythmia, ischemic heart disease, etc., resulting from an inability to utilize long-chain fatty acids, which are main cardiovascular energy source, and the accumulation of neutral fats in cells. Due to progress in the research and development of CNT-01, this disease has gradually come to be known overseas. On November, 2019, the disease was registered in Orphanet, the international portal on rare diseases supervised by INSERM (The French National Institute of Health and Medical Research), as unit disease (ORPHA code: 565612). The launch of CNT-01 is strongly anticipated in treatment settings, as there are currently no drugs approved for the indication of TGCV, either in Japan or abroad.
Through the signing of this agreement, TOA EIYO and Osaka University will continue to strive for the development and promotion of CNT-01 as soon as possible, to contribute to the treatment of TGCV.
About TOA EIYO Ltd.
TOA EIYO Ltd., based in Tokyo, Japan, is a company dedicated to contributing to the health of people through unique medicines primarily in the cardiovascular fields. TOA EIYO aims to be a specialized pharmaceutical company that is truly indispensable to the medical front lines via our research and development of new medicines and value-added generic drugs in the cardiovascular fields including ischemic heart disease, arrhythmia and heart failure, and other related fields. For more information, please visit our website at https://www.toaeiyo.co.jp/english/
About National University Corporation Osaka University
Originating from Kaitokudo and Tekijuku, two places of learning established in Osaka during the Edo period, Osaka University was founded in 1931 as Japan’s sixth imperial university, due to strong demand from both the citizens, and the government and business sectors of Osaka. Currently comprising 11 faculties, 16 graduate schools, and 6 research institutes, Osaka University continues to develop as a leading comprehensive research university. In line with its key concept of “Co-creation” with society, Osaka University conducts creative activities in cooperation with society, with the goal of becoming a “World-Leading Innovative University Contributing to Social Change” by 2031, at which time it will celebrate the 100th Anniversary of its founding.
For more information, please visit https://www.osaka-u.ac.jp/en